Clinical Trials Logo

Ductus Arteriosus, Patent clinical trials

View clinical trials related to Ductus Arteriosus, Patent.

Filter by:

NCT ID: NCT01291654 Recruiting - Clinical trials for Patent Ductus Arteriosus

Paracetamol and Patent Ductus Arteriosus (PDA)

Start date: April 2012
Phase: Phase 2
Study type: Interventional

The investigators propose that paracetamol will be similarly effective to ibuprofen in treating PDA in the premature neonate, with fewer side effects.

NCT ID: NCT01261117 Completed - Clinical trials for Patent Ductus Arteriosus

Efficacy and Safety of Oral Versus Intravenous Ibuprofen for PDA Treatment in ELBW Infants

Start date: January 2009
Phase: N/A
Study type: Interventional

To determine whether oral or intravenous ibuprofen has a better or same efficacy and tolerance in closure of patent ductus arteriosis in extremely-low-birth-weight preterm infants.

NCT ID: NCT01251939 Completed - Clinical trials for Ductus Arteriosus, Patent

Changes in Renal and Splanchnic Oxygenation During Ibuprofen Treatment for Patent Ductus Arterious

Start date: October 2011
Phase: N/A
Study type: Observational

Patent ductus arterious(PDA)is frequently seen and potentially pathologic in preterm infants. Near-infrared spectroscopy is a simple bedside tool to analyse the changes in the renal and splanchnic tissue oxygenation index and fractional tissue oxygen extraction and may be helpful to measure effects of ibuprofen treatment for PDA in preterm infants.

NCT ID: NCT01243996 Completed - Clinical trials for Ductus Arteriosus, Patent

High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infant

Start date: June 2008
Phase: Phase 2/Phase 3
Study type: Interventional

The investigators hypothesized that the early treatment of PDA with ibuprofen doses higher than those actually recommended might increase the closure rate in preterm infants with gestational age <29 weeks without increasing the occurrence of associated adverse effects. To assess this hypothesis the investigators planned a multicenter randomized controlled study to compare the effectiveness of the current ibuprofen regimen to that of a high-dose regimen in closing PDA.

NCT ID: NCT01070745 Withdrawn - Clinical trials for Patent Ductus Arteriosus

Second Course of Therapy for Resistant Patent Ductus Arteriosus (PDA)

Start date: June 2010
Phase: Phase 2
Study type: Interventional

Patency of the ductus arteriosus (PDA) is functionally essential for fetal circulation, however persistence of ductal patency postnatally may have significant adverse hemodynamic effects in the neonate. Medical therapy for PDA predominantly involves the administration of one of two non-steroidal anti-inflammatory drugs: indomethacin or ibuprofen. Both of these therapies have been shown to be successful in mediating ductal closure in approximately 70% of treated infants. However, the need for a second course of treatment for PDA closure remains quite common. The investigators hypothesize that, because of small differences between the two drugs, a greater percentage of infants who did not respond to a first course of therapy with indomethacin will respond to a second course with ibuprofen than to a repeat course of indomethacin. As such, the investigators aim to compare secondary therapy with a repeat course of indomethacin to secondary therapy with ibuprofen in infants whose ductus remained patent after a first course of therapy with indomethacin.

NCT ID: NCT01032785 Recruiting - Clinical trials for Closure of the Foramen Ovale and Ductus Arteriosus

Timing of Closure of Patent Foramen Ovale Following Birth

Start date: December 2009
Phase: N/A
Study type: Observational

It is known that the foramen ovale closes in most infants during the first 6 months of life, however, most of the important papers in the field concentrated on observing infants with murmurs and following those with patent foramen ovale by echocardiography until 6-24 months. The purpose of this study is to observe the natural profile of closure of the foramen ovale and ductus arteriosus for the first 36 hours after birth. This understanding may help to avoid unnecessary treatment and exams for newborns with findings that are natural for their stage of development.

NCT ID: NCT01031316 Completed - Clinical trials for Ductus Arteriosus, Patent

Patent Ductus Arteriosus (PDA) Screening Trial

Start date: October 2009
Phase: N/A
Study type: Interventional

The ductus arteriosus directs blood away from the pulmonary circulation and toward the systemic circulation during fetal life, then closes after birth. In preterm infants the incidence of spontaneous closure decreases with gestational age. Patent ductus arteriosus (PDA) increases the risks of bronchopulmonary dysplasia (BPD) and necrotizing enterocolitis (NEC). However, this association may not be a causal relationship. Echocardiography is required to diagnose PDA. However, routine screening echocardiograms lead to detection of asymptomatic PDAs, for which the benefit of therapy remains unproven. A randomized controlled trial has been designed in which 88 infants with birth weight less than or equal to 1250 grams and gestational age less than or equal to 30 weeks will be enrolled. The investigators' goal is to determine how screening echocardiography influences clinical management and outcomes in these infants.

NCT ID: NCT01028183 Withdrawn - Clinical trials for Gastroesophageal Reflux

Impact of Maternal-infant Therapeutics on Safety, Mortality, and Disability

Start date: August 2010
Phase: N/A
Study type: Observational

The purpose of this research is to address the comparative effectiveness and harm of the therapeutics frequently given to pregnant women and their young infants including antibiotics, tocolytic agents, non-steroidal anti-inflammatory drugs, H2 blockers, and steroids. Our overall hypothesis is that the use of an existing electronic medical record with additional resources for precise data collection and 18 month follow up will successfully address current knowledge gaps in therapeutic effectiveness and relative therapeutic harm. We will use an existing electronic medical record into which detailed healthcare information is entered for over 100,000 newborns each year. These infants will comprise the "Source Cohort". Nested within that database, we will prospectively enroll 10% of the population (10,000 newborns) as the Follow-Up Cohort. The current electronic medical record for the Source Cohort does not capture therapeutic dosing with sufficient precision to conduct comparative effectiveness research sufficient to change medical practice. The proposed research will: 1) ensure accurate data collection through electronic monitoring and real-time quality assurance evaluation in the Source Cohort; and 2) conduct 18 months post-hospital follow-up for neurologic outcomes and disability for the Follow-Up Cohort. We will complete assessments of neurologic outcomes and disability using an interactive web-based system, mail, telephone follow up, and in-person examination.

NCT ID: NCT00961753 Terminated - Clinical trials for Patent Ductus Arteriosus

Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates

OIDS
Start date: August 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if increasing the ibuprofen dose will increase the likelihood of closing the patent ductus arteriosus in premature babies.

NCT ID: NCT00833365 Terminated - Prematurity Clinical Trials

Early Versus Late Use of Ibuprofen for PDA Closure

Start date: January 2009
Phase: N/A
Study type: Interventional

The primary objective is to evaluate the PDA closure rate of early vs. late use of Ibuprofen (Ibu). The investigators believe that early use of Ibu will have a higher PDA closure rate than later use of Ibu. Early use is defined as medication given before the infant reaches 96 hrs old. Late use is defined as medication given when infant is more than 96 hrs old. The secondary objective is to measure the stress hormone and metabolic response (plasma catecholamines, glucose, and lactate) of neonates undergoing Ibu treatment of the PDA. The investigators believe that early ibuprofen will blunt the stress response greater than later use.